Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression.

about

The Akt pathway in oncology therapy and beyond (Review)

P2860

Q58555910-C96B199C-1A8A-4FAD-BC23-36DC6488299A

P2860

Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression.

Item

http://www.wikidata.org/entity/Q42368110

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Propofol enhances BCR-ABL TKIs ...... through Akt/mTOR suppression.

@en

Propofol enhances BCR-ABL TKIs ...... through Akt/mTOR suppression.

@nl

type

Item

label

Propofol enhances BCR-ABL TKIs ...... through Akt/mTOR suppression.

@en

Propofol enhances BCR-ABL TKIs ...... through Akt/mTOR suppression.

@nl

prefLabel

Propofol enhances BCR-ABL TKIs ...... through Akt/mTOR suppression.

@en

Propofol enhances BCR-ABL TKIs ...... through Akt/mTOR suppression.

@nl

P1476

Propofol enhances BCR-ABL TKIs ...... a through Akt/mTOR suppression

@en

P2093

Aixia Peng

http://www.w3.org/2001/XMLSchema#string

Jingwen Xu

http://www.w3.org/2001/XMLSchema#string

Zhimin Tan

http://www.w3.org/2001/XMLSchema#string

P2860

Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation

Anticancer properties of propofol-docosahexaenoate and propofol-eicosapentaenoate on breast cancer cells

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

Chronic myeloid leukemia.

Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.

Characteristics and survival of BCR/ABL negative chronic myeloid leukemia: a retrospective analysis of the Surveillance, Epidemiology and End Results database.

The protective effects of propofol against CoCl2-induced HT22 cell hypoxia injury via PP2A/CAMKIIα/nNOS pathway.

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

P2888

s12871-017-0423-2

P304

132

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12871-017-0423-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mingwen Ouyang

P577

2017-09-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1091989838

http://www.w3.org/2001/XMLSchema#string

P698

28962554

http://www.w3.org/2001/XMLSchema#string

P921

propofol

chronic myeloid leukemia

P932

5622516

http://www.w3.org/2001/XMLSchema#string

Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression.

about

P2860

P2860

Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921

P932